Roadshow
AnHorn Medicines' AIMCADD®
AnHorn Medicines spearheads protein degradation innovation, pioneering novel therapeutics to tackle previously unaddressed proteins. Powered by AI, our drug discovery platform facilitates the creation of protein degraders, including PROTACs and molecular glues.
AnHorn Medicines' AIMCADD® is a proprietary artificial intelligence-driven drug discovery platform, facilitates the design and optimization of small-molecule inhibitors and degraders, enabling the identification of drug candidates that can selectively target and degrade disease-causing proteins.
- Established 2020
- Company AnHorn Medicines
- Telephone +886-2-2786-2568
- Email ywlin@anhornmed.com
- Address C522, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 115021, Taiwan (R.O.C.)
AnHorn Medicines was founded in 2020, the first AI-driven new drug discovery company in Taiwan to successfully advance a program into clinical trials. AnHorn is pioneering new treatments for conditions with worldwide unmet medical needs. AH-001 is the company’s first leading program through its AI-driven platform, exemplifying its mission to create breakthrough therapies that improve patient outcomes.